Sarepta Therapeutics News
It can pay off to keep an eye on the most successful investors out there.
3 pointers to help make biotech investing for beginners a little less intimidating.
Sarepta Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)
An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
If there are any bears left, I hope they aren't trying to short during this bull rampage.
It isn't easy in this market, but two stocks are on my radar this morning.
Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care InnovationMay 16
Sarepta Therapeutics was a winner within the drugs industry, rising $0.58 (1.7%) to $35.51 on light volume
Sarepta Therapeutics , a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following investor conferences in May. Chris Garabedian, Sarepta's president ...
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Sarepta Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript